Rigel Pharmaceuticals Inc.

NAS: RIGL

GO
/marketstate/country/us

Market open

 --Real time quotes

Oct 22, 2021, 9:43 a.m.

/zigman2/quotes/207222917/composite

$

3.22

Change

-0.06 -1.89%

Volume

Volume 69,537

Real time quotes

/zigman2/quotes/207222917/composite

Previous close

$ 3.28

$ 3.22

Change

-0.06 -1.89%

Day low

Day high

$3.21

$3.25

Open

52 week low

52 week high

$2.36

$5.50

Open

Company Description

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease...

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Valuation

Price to Sales Ratio

5.44

Price to Book Ratio

17.42

Enterprise Value to Sales

5.27

Total Debt to Enterprise Value

0.07

Efficiency

Revenue/Employee

642,728.00

Income Per Employee

-176,000.00

Receivables Turnover

8.33

Total Asset Turnover

0.84

Liquidity

Current Ratio

2.18

Quick Ratio

2.04

Cash Ratio

1.40

Profitability

Gross Margin

99.18

Operating Margin

-26.67

Pretax Margin

-27.38

Net Margin

-27.38

Return on Assets

-23.06

Return on Equity

-67.72

Return on Total Capital

-35.50

Return on Invested Capital

-40.37

Capital Structure

Total Debt to Total Equity

114.87

Total Debt to Total Capital

53.46

Total Debt to Total Assets

35.41

Long-Term Debt to Equity

89.54

Long-Term Debt to Total Capital

41.67

Officers and Executives

Name Age Officer Since Title
Mr. Raul R. Rodriguez 58 2000 President, Chief Executive Officer & Director
Mr. Dean L. Schorno 56 2018 Chief Financial Officer & Executive Vice President
Dr. Wolfgang Dummer 53 2019 Chief Medical Officer & Executive Vice President
Mr. David Santos - 2020 Chief Commercial Officer & Executive VP
Mr. Joseph Lasaga - 1998 SVP-Business Development & Alliance Management

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/19/2021 Bradford S. Goodwin
Director
25,000   Award at $0 per share. 0
05/19/2021 Walter H. Moos
Director
25,000   Award at $0 per share. 0
05/19/2021 Gregg Anthony Lapointe
Director
25,000   Award at $0 per share. 0
05/19/2021 Keith A. Katkin
Director
25,000   Award at $0 per share. 0
05/19/2021 Gary A. Lyons
Director
25,000   Award at $0 per share. 0
05/19/2021 Jane Wasman
Director
25,000   Award at $0 per share. 0
05/19/2021 Brian L. Kotzin
Director
25,000   Award at $0 per share. 0
05/19/2021 Alison L. Hannah
Director
6,250   Award at $0 per share. 0
05/22/2019 Dean L. Schorno
EVP &Chief Financial Officer
3,274   Acquisition at $2.13 per share. 6,973
05/22/2019 Dean L. Schorno
EVP &Chief Financial Officer
46,726   Acquisition at $2.13 per share. 99,526
10/12/2018 Nelson D. Cabatuan
Principal Accounting Officer
10,000   Disposition at $3.12 per share. 31,200
09/17/2018 Anne-Marie S. Duliege
EVP & Chief Medical Officer
37,500   Disposition at $3.5 per share. 131,250
09/17/2018 Anne-Marie S. Duliege
EVP & Chief Medical Officer
115,500   Disposition at $3.5 per share. 404,250
09/17/2018 Anne-Marie S. Duliege
EVP & Chief Medical Officer
37,500   Derivative/Non-derivative trans. at $2.11 per share. 79,125
09/17/2018 Anne-Marie S. Duliege
EVP & Chief Medical Officer
115,500   Derivative/Non-derivative trans. at $2.54 per share. 293,370
09/11/2018 Eldon C. Mayer
EVP & Chief Commercial Officer
50,000   Acquisition at $3.23 per share. 161,500
09/10/2018 Eldon C. Mayer
EVP & Chief Commercial Officer
50,000   Acquisition at $3.28 per share. 164,000
09/04/2018 Anne-Marie S. Duliege
EVP & Chief Medical Officer
16,500   Disposition at $3.51 per share. 57,915
09/04/2018 Anne-Marie S. Duliege
EVP & Chief Medical Officer
16,500   Derivative/Non-derivative trans. at $2.54 per share. 41,910
08/23/2018 Eldon C. Mayer
EVP & Chief Commercial Officer
100,000   Acquisition at $2.82 per share. 282,000
08/17/2018 Raul R. Rodriguez
CEO, President; Director
114,000   Acquisition at $2.63 per share. 299,820
07/02/2018 Anne-Marie S. Duliege
EVP & Chief Medical Officer
5,000   Disposition at $2.79 per share. 13,950
/news/latest/company/us/rigl

MarketWatch News on RIGL

  1. Rising drug prices continue to hit seniors

    6:05 a.m. July 6, 2021

    - Paul Brandus

  2. Riell shares jump 31% premarket

    7:38 a.m. Feb. 18, 2021

    - Ciara Linnane

  3. Eli Lilly to pay Rigel $125 mln upfront, up to $835 mln in future milestone payments

    7:37 a.m. Feb. 18, 2021

    - Ciara Linnane

  4. Eli Lilly and Rigel to codevelop Rigel's treatment for immunological and neurodegenerative diseases

    7:37 a.m. Feb. 18, 2021

    - Ciara Linnane

  5. Rigel Pharmaceuticals downgraded to neutral and overweight at J.P. Morgan

    10:27 a.m. Nov. 9, 2020

    - Tomi Kilgore

  6. Rigel Pharmaceuticals downgraded to neutral from overweight at J.P. Morgan

    8:05 a.m. Nov. 9, 2020

    - Tomi Kilgore

  7. Rigel Pharmaceuticals stock price target raised to $7 from $6 at J.P. Morgan

    7:26 a.m. Sept. 4, 2018

    - Tomi Kilgore

  8. Rigel Pharmaceuticals stock price target raised to $8 from $6 at BMO Capital

    9:26 a.m. April 18, 2018

    - Tomi Kilgore

  9. Rigel announces FDA approval, for real this time

    5:35 p.m. April 17, 2018

    - Jeremy C. Owens

  10. News that made Rigel stock pop was a mistake, Rigel says

    4:29 p.m. April 12, 2018

    - Jeremy C. Owens

  11. Rigel Pharmaceuticals CFO Ryan Maynard resigns after 7 1/2-years in the role

    8:35 a.m. Dec. 15, 2017

    - Tomi Kilgore

  12. Barron’s After Hours: Hess Jumps, Jabil Gains, Oracle Sinks

    9:31 p.m. Dec. 14, 2017

    - Barrons Blogs

  13. Charting the Market

    1:46 a.m. Oct. 7, 2017

    - Barron's Online

  14. Loading more headlines...
/news/nonmarketwatch/company/us/rigl

Other News on RIGL

  1. Rigel (RIGL) COVID-19 Treatment Denied By FDA for EUA

    10:27 a.m. Aug. 16, 2021

    - Zacks.com

  2. SoFi Technologies, Cricut, FIGS among premarket losers' pack

    8:54 a.m. Aug. 13, 2021

    - Seeking Alpha

  3. 10-Q: RIGEL PHARMACEUTICALS INC

    4:08 p.m. Aug. 3, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  4. Rigel Pharmaceuticals EPS beats by $0.04, beats on revenue

    4:07 p.m. Aug. 3, 2021

    - Seeking Alpha

  5. 3 Biotech Stocks That Could Rocket Higher

    6:37 a.m. July 24, 2021

    - Motley Fool

  6. A Recommendation For Rigel Pharmaceuticals

    10:42 a.m. May 16, 2021

    - Seeking Alpha

  7. Loading more headlines...

At a Glance

Rigel Pharmaceuticals, Inc.

1180 Veterans Boulevard

South San Francisco, California 94080-1985

Phone

1 6506241100

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$108.62M

Net Income

$-29.74M

2020 Sales Growth

83.2%

Employees

169.00

/news/pressrelease/company/us/rigl

Press Releases on RIGL

  1. Rigel to Participate in Three Upcoming Investor Conferences

    7:30 a.m. Sept. 2, 2021

    - PR Newswire - PRF

  2. Rigel Pharmaceuticals Provides Update on COVID-19 Program

    7:30 a.m. Aug. 13, 2021

    - PR Newswire - PRF

  3. Top Biotech Penny Stocks to Buy This Week? 9 To Watch

    2:36 p.m. July 6, 2021

    - Penny Stocks

  4. Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial

    7:30 a.m. June 29, 2021

    - PR Newswire - PRF

  5. Top Penny Stocks to Buy in July? 7 You May Not Know About

    4:06 p.m. June 28, 2021

    - Penny Stocks

  6. Loading more headlines...
Trending Tickers
  • /zigman2/quotes/200467500/composite NVDA+6.20%
  • /zigman2/quotes/201948298/composite BABA-5.69%
  • /zigman2/quotes/202092269/composite ENSC+36.10%
  • /zigman2/quotes/200164174/composite SNOA+74.50%
  • /zigman2/quotes/207683784/composite TIGR-10.38%
X
Powered by StockTwits
Link to MarketWatch's Slice.